PCDHGB5

Across TCGA pan-cancer cohorts, PCDHGB5 RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of PCDHGB5’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where PCDHGB5 RNA is repressed in tumor relative to normal tissue. In most cancer types PCDHGB5 is over-expressed in tumor, although a few such as KIRC and UCEC show the opposite, repressed pattern.

KIRC, UCEC, and LUSC are the cancer types where PCDHGB5 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PCDHGB5 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	IV	−1.479	<.001	11	view →
UCEC	All	All	−1.615	<.001	6	view →
LUSC	All	II,III,IV	−0.942	<.001	5	view →
COAD	Female	II,III,IV	−0.678	<.001	5	view →
STAD	All	All	−0.596	.001	5	view →
BRCA	All	All	−0.464	<.001	4	view →
CHOL	All	II,III,IV	+2.260	.003	3	view →
KICH	All	All	−0.834	.001	3	view →
READ	Female	All	−1.302	<.001	2	view →
THCA	All	II,III,IV	−0.533	.032	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

PCDHGB5–KIRC

Open the KIRC breakdown →